Compare · KIDS vs WST
KIDS vs WST
Side-by-side comparison of OrthoPediatrics Corp. (KIDS) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both KIDS and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $24.89B, about 49.6x KIDS ($501.4M).
- Over the past year, KIDS is down 10.9% and WST is up 67.8% - WST leads by 78.7 points.
- WST has been more active in the news (5 items in the past 4 weeks vs 1 for KIDS).
- WST has more recent analyst coverage (18 ratings vs 8 for KIDS).
- Company
- OrthoPediatrics Corp.
- West Pharmaceutical Services Inc.
- Price
- $19.48+1.35%
- $352.54-1.57%
- Market cap
- $501.4M
- $24.89B
- 1M return
- +7.24%
- +9.06%
- 1Y return
- -10.89%
- +67.76%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2017
- News (4w)
- 1
- 5
- Recent ratings
- 8
- 18
OrthoPediatrics Corp.
OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc tibia, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, Spica Tables, RESPONSE Spine systems, Bandloc, Pediguard, Pediatric Nailing Platform, Femur system, Orthex, QuickPack, and ApiFix Mid-C system. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest KIDS
- Amendment: SEC Form SCHEDULE 13G/A filed by OrthoPediatrics Corp.
- OrthoPediatrics Announces Distribution Agreement with OSSIO, Inc. to Provide Revolutionary Orthopedic Fixation Technology to U.S. Children’s Hospitals Nationwide
- Director Pelizzon David R was granted 11,436 shares, increasing direct ownership by 35% to 44,384 units (SEC Form 4)
- Director Fischer Kelly Laine was granted 11,436 shares, increasing direct ownership by 263% to 15,781 units (SEC Form 4)
- Director Ruf Harold was granted 11,436 shares, increasing direct ownership by 136% to 19,837 units (SEC Form 4)
- Director Hughes Bryan W was granted 11,436 shares, increasing direct ownership by 54% to 32,663 units (SEC Form 4)
- Director Riccitelli Samuel D was granted 11,436 shares, increasing direct ownership by 56% to 31,859 units (SEC Form 4)
- Director Dyer George Sinclair Mitchell was granted 11,436 shares, increasing direct ownership by 87% to 24,568 units (SEC Form 4)
- Director Mcdonald Jimmy Duane was granted 11,436 shares, increasing direct ownership by 87% to 24,568 units (SEC Form 4)
- Director Throdahl Mark C was granted 11,436 shares, increasing direct ownership by 7% to 179,317 units (SEC Form 4)
Latest WST
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- BNP Paribas Exane initiated coverage on West Pharm with a new price target
- West to Host Second-Quarter 2026 Conference Call
- SEC Form 4 filed by Director Haugen Janet Brutschea
- West Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System
- West Pharm upgraded by Barclays with a new price target
- Wolfe Research resumed coverage on West Pharm with a new price target
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- West Appoints Michel Lagarde to be President and Chief Executive Officer
- Amendment: West Pharmaceutical Services Inc. filed SEC Form 8-K: Financial Statements and Exhibits